News for Polyphor AG (POLN.SW)

Published at

Sep 29, 2023 7:20 AM

by marketscreener.com

neutral

neutral

Spexis : Half Year Report 2023 -September 29, 2023 at 01:20 am EDT

Half-Year Report2023 Interim condensed consolidated financial statements as at June 30, 2023 Spexis Ltd and its...

PPHOF POLN.SW

Read more →
Published at

May 25, 2023 11:44 AM

by marketscreener.com

positive

positive

Destiny Pharma picks interim CEO as Clark makes quick exit

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Chief Executive Officer Neil Clark steps down immediately to... | May 25, 2023

ROGN.MX ROG.SW RO.SW RHHVF RHHBY RHHBF PPHOF POLN.SW NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA DEST.L 0TDF.L 0QQ6.L 0K9E.L

Read more →
Published at

Jan 26, 2022 7:00 PM

by globenewswire.com

mixed

mixed

Cystic Fibrosis Pipeline Offers Promising New Options for Treatment | DelveInsight

The Cystic Fibrosis (CF) therapeutic development pipeline contains candidate drugs that address many different aspects of the disease. Drug development for...

VRNA TBIO PPHOF POLN.SW ELOX CALA ARWR ARDS KRYS INSM GXE.DE GLPGF GLPG.AS GLPG 0JAV.L

Read more →
Published at

Dec 30, 2021 7:21 AM

by marketscreener.com

positive

positive

Polyphor closes merger with EnBiotix and is renamed Spexis

EQS-Ad-hoc: Polyphor AG / Key word: Merger Polyphor closes merger with EnBiotix and is renamed Spexis 30-Dec-2021 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The... | December 30, 2021

PPHOF POLN.SW

Read more →
Published at

Dec 29, 2021 8:30 AM

by financialpost.com

neutral

neutral

EnBiotix, Inc. Closes $11M Pre-Merger Financing

BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) — EnBiotix, Inc. , a rare disease company currently focused on chronic respiratory disorders, today announced the…

VEGPF VEC.L PPHOF POLN.SW

Read more →
Published at

Dec 15, 2021 7:15 AM

by markets.businessinsider.com

positive

positive

EQS-Adhoc: Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin

EQS-Ad-hoc: Polyphor AG / Key word(s): Study Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inha...

PPHOF POLN.SW

Read more →
Published at

Nov 11, 2021 12:46 PM

by marketscreener.com

mixed

mixed

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

- Mr. O’Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - ... | November 11, 2021

TXMD PPHOF POLN.SW BNTXN.MX BNTX 0A3M.L

Read more →
Published at

Nov 11, 2021 12:45 PM

by thestreet.com

mixed

mixed

TherapeuticsMD Announces Leadership Changes; Appointment Of Industry Veteran, Hugh O'Dowd, As Chief Executive Officer

TherapeuticsMD, Inc. TXMD (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the

TXMD PPHOF POLN.SW BNTXN.MX BNTX 0A3M.L

Read more →
Published at

Oct 15, 2021 7:32 AM

by marketscreener.com

neutral

neutral

La Commission des OPA constate l'absence d'obligation de pr?nter une offre publique d'acquisition dans le cadre de la fusion pr?e avec EnBiotix

EQS Group-Ad-hoc: Polyphor AG / Mot-clé : Fusion de sociétés La Commission des OPA constate l'absence d'obligation de présenter une offre publique d'acquisition dans le cadre de la fusion prévue... | October 15, 2021

PPHOF POLN.SW

Read more →
Published at

Oct 15, 2021 7:32 AM

by marketscreener.com

neutral

neutral

Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger

EQS Group-Ad-hoc: Polyphor AG / Key word: Merger Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger 15-Oct-2021 /... | October 15, 2021

PPHOF POLN.SW

Read more →
Published at

Oct 14, 2021 6:32 PM

by valueandopportunity.com

mixed

mixed

All Swiss Shares Part 15 – Nr. 141-150

Moving forward with another 10 almost randomly selected Swiss stocks. This time, only one stock looked interesting but in that case so interesting that I initiated a 1% starter position. 141. ASMALLWORLD AG ASMALLWORLD is a 36.4 mn CHF market cap company that was IPOed in 2018 at 9,75 CHF per share, climbed to over…

VZUG.SW PPHOF POLN.SW MOBN.SW ASWN.SW 0QQY.L ESUN.SW

Read more →